MURA PE Ratio & Valuation,Is MURA Overvalued

MURA Relative Valuation

MURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MURA is overvalued; if below, it's undervalued.

Historical Valuation

Mural Oncology PLC (MURA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.64. The fair price of Mural Oncology PLC (MURA) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：2.04

Fair

-1.19

0.68

EV/EBITDA

Mural Oncology PLC. (MURA) has a current EV/EBITDA of 0.68. The 5-year average EV/EBITDA is 0.82. The thresholds are as follows: Strongly Undervalued below -0.52, Undervalued between -0.52 and 0.15, Fairly Valued between 1.48 and 0.15, Overvalued between 1.48 and 2.15, and Strongly Overvalued above 2.15. The current Forward EV/EBITDA of 0.68 falls within the Historic Trend Line -Fairly Valued range.

0.64

EV/EBIT

Mural Oncology PLC. (MURA) has a current EV/EBIT of 0.64. The 5-year average EV/EBIT is 0.74. The thresholds are as follows: Strongly Undervalued below -0.48, Undervalued between -0.48 and 0.13, Fairly Valued between 1.35 and 0.13, Overvalued between 1.35 and 1.96, and Strongly Overvalued above 1.96. The current Forward EV/EBIT of 0.64 falls within the Historic Trend Line -Fairly Valued range.

0.00

Mural Oncology PLC. (MURA) has a current PS of 0.00. The 5-year average PS is 0.08. The thresholds are as follows: Strongly Undervalued below -1.02, Undervalued between -1.02 and -0.47, Fairly Valued between 0.64 and -0.47, Overvalued between 0.64 and 1.19, and Strongly Overvalued above 1.19. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Mural Oncology PLC. (MURA) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.33. The thresholds are as follows: Strongly Undervalued below -0.88, Undervalued between -0.88 and -0.60, Fairly Valued between -0.05 and -0.60, Overvalued between -0.05 and 0.22, and Strongly Overvalued above 0.22. The current Forward P/OCF of 0.00 falls within the Overvalued range.

0.00

P/FCF

Mural Oncology PLC. (MURA) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.32. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and -0.53, Fairly Valued between -0.10 and -0.53, Overvalued between -0.10 and 0.12, and Strongly Overvalued above 0.12. The current Forward P/FCF of 0.00 falls within the Overvalued range.

Mural Oncology PLC (MURA) has a current Price-to-Book (P/B) ratio of 0.64. Compared to its 3-year average P/B ratio of -0.21 , the current P/B ratio is approximately -401.49% higher. Relative to its 5-year average P/B ratio of -0.21, the current P/B ratio is about -401.49% higher. Mural Oncology PLC (MURA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -293.04%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -293.04% , the current FCF yield is about -100.00% lower.

0.64

P/B

Median3y

-0.21

Median5y

-0.21

-334.77

FCF Yield

Median3y

-293.04

Median5y

-293.04

Competitors Valuation Multiple

The average P/S ratio for MURA's competitors is 8.37, providing a benchmark for relative valuation. Mural Oncology PLC Corp (MURA) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MURA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MURA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Mural Oncology PLC (MURA) currently overvalued or undervalued?

What is Mural Oncology PLC (MURA) fair value?

MURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mural Oncology PLC (MURA) is between to according to relative valuation methord.

How does MURA's valuation metrics compare to the industry average?

The average P/S ratio for MURA's competitors is 8.37, providing a benchmark for relative valuation. Mural Oncology PLC Corp (MURA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Mural Oncology PLC (MURA) as of Dec 15 2025?

As of Dec 15 2025, Mural Oncology PLC (MURA) has a P/B ratio of 0.64. This indicates that the market values MURA at 0.64 times its book value.

What is the current FCF Yield for Mural Oncology PLC (MURA) as of Dec 15 2025?

As of Dec 15 2025, Mural Oncology PLC (MURA) has a FCF Yield of 0.00%. This means that for every dollar of Mural Oncology PLC’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Mural Oncology PLC (MURA) as of Dec 15 2025?

As of Dec 15 2025, Mural Oncology PLC (MURA) has a Forward P/E ratio of -1.19. This means the market is willing to pay $-1.19 for every dollar of Mural Oncology PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Mural Oncology PLC (MURA) as of Dec 15 2025?

As of Dec 15 2025, Mural Oncology PLC (MURA) has a Forward P/S ratio of 0.00. This means the market is valuing MURA at $0.00 for every dollar of expected revenue over the next 12 months.

MURA Valuation

MURA Valuation

MURA Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Mural Oncology PLC (MURA) currently overvalued or undervalued?

What is Mural Oncology PLC (MURA) fair value?

How does MURA's valuation metrics compare to the industry average?

What is the current P/B ratio for Mural Oncology PLC (MURA) as of Dec 15 2025?

What is the current FCF Yield for Mural Oncology PLC (MURA) as of Dec 15 2025?

What is the current Forward P/E ratio for Mural Oncology PLC (MURA) as of Dec 15 2025?

What is the current Forward P/S ratio for Mural Oncology PLC (MURA) as of Dec 15 2025?